Printer Friendly

J&J Helps Advance Rx Via New Collaborations.

Johnson & Johnson is engaged in more than a dozen new collaborations to spur the development of novel health care solutions. Earlier this month, the company's Johnson & Johnson Innovation unit said its latest deals leverage advances in science and technology to address areas of high unmet medical need, including the use of artificial intelligence to detect signs of Alzheimer's disease years before it becomes apparent; the identification of throat cancers with a saliva test; and harnessing the microbiome to treat sleep disorders. Some of the other new collaborations focus on preventing psoriasis; discovering novel therapeutics for obesity; preventing, intercepting and curing lung cancer; harnessing bacteria to fight skin disease; and fighting Alzheimer's disease with gene therapy. "Each collaboration represents a unique opportunity to explore novel therapeutics, medical devices and consumer health solutions," stated Paul Stoffels, executive vice president and chief scientific officer at Johnson & Johnson. "By advancing transformative health care innovations together with entrepreneurs, academic centers and institutions, we are one step closer to addressing many pressing global health care challenges."

COPYRIGHT 2018 Racher Press, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Rx Update; Johnson & Johnson
Publication:Chain Drug Review
Article Type:Brief article
Date:Jan 15, 2018
Previous Article:Mallinckrodt Set to Acquire Sucampo.
Next Article:Takeda to acquire stem cell specialist TiGenix.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |